Synergistic effect of thrombus aspiration and glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention

被引：0
|
作者：
Pyxaras, S. A. [1 ]
Mangiacapra, F. [1 ]
Di Serafino, L. [1 ]
Toth, G. [1 ]
De Vroey, F. [1 ]
Perkan, A. [2 ]
De Bruyne, B. [1 ]
Salvi, A. [2 ]
Sinagra, G. [2 ]
机构：
[1] OLV Hosp Aalst, Ctr Cardiovasc, Aalst, Belgium
[2] Univ Hosp Riuniti, Dept Cardiol, Trieste, Italy
来源：
EUROPEAN HEART JOURNAL | 2012年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：549 / 550
页数：2
相关论文
共 50 条
  • [31] Glycoprotein IIb/IIIa inhibitor therapy and outcomes after percutaneous coronary intervention
    Tepper, RI
    Simonian, N
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (06): : 771 - 772
  • [32] New platelet glycoprotein IIb/IIIa inhibitor trials in percutaneous coronary intervention
    Topol, EJ
    [J]. JOURNAL OF INVASIVE CARDIOLOGY, 1999, 11 : 3C - 6C
  • [33] CLINICAL OUTCOMES IN PATIENTS TREATED WITH GLYCOPROTEIN IIB/IIIA INHIBITORS DURING PRIMARY PERCUTANEOUS CORONARY INTERVENTION ACCORDING TO ARTERIAL ACCESS SITE
    Krishnamurthy, Arvindra
    Keeble, Claire
    Anderson, Michelle
    Somers, Kathryn
    Burton-Wood, Natalie
    Harland, Charlotte
    Baxter, Paul
    McLenachan, James
    Blaxill, Jonathan
    Blackman, Daniel
    Malkin, Christopher
    Wheatcroft, Stephen
    Greenwood, John
    [J]. HEART, 2018, 104 : A14 - A15
  • [34] Impact of multivessel disease on myocardial perfusion and survival among patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitors
    De Luca, Giuseppe
    Gibson, Michael
    Cutlip, Donald
    Huber, Kurt
    Dudek, Dariusz
    Bellandi, Francesco
    Noc, Marko
    Maioli, Mauro
    Zorman, Simona
    Zeymer, Uwe
    Secco, Gioel Gabrio
    Gabriel, Henrique Mesquita
    Emre, Ayse
    Arntz, Hans-Richard
    Rakowski, Tomasz
    Gyongyosi, Maryann
    van't Hof, Arnoud W. J.
    [J]. ARCHIVES OF CARDIOVASCULAR DISEASES, 2013, 106 (03) : 155 - 161
  • [35] Platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention - Focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide
    Gilchrist, IC
    [J]. CLINICAL PHARMACOKINETICS, 2003, 42 (08) : 703 - 720
  • [36] Aspiration of Embolized Thrombus During Primary Percutaneous Coronary Intervention
    Stoel, Martin G.
    von Birgelen, Clemens
    Zijlstra, Felix
    [J]. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2009, 73 (06) : 781 - 786
  • [37] Comparison of abciximab and small molecule platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention: A quantitative review
    Brown, DL
    Fann, CSJ
    Chang, CJ
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (02) : 84A - 84A
  • [38] An audit of the use and complications of glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention against national UK standards
    Sheikh, Azeem
    Baig, Kamran
    [J]. CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2006, 7 (04) : 237 - 239
  • [39] Comparison of heparin and bivalirudin in patients undergoing percutaneous coronary intervention without use of glycoprotein IIb/IIIa inhibitors
    Abtahian, Farhad
    Waldo, Stephen
    Jang, Ik-Kyung
    [J]. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2015, 86 (03) : 390 - 396
  • [40] Glycoprotein IIb/IIIa inhibition in percutaneous coronary interventions
    Sharma, S
    Nyitray, W
    Bhambi, B
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (11): : 1451 - 1451
12345